Dr. Andrés Cruz-Herranz, MD, PhD, is a neurologist, neuroscientist, and Associate Medical Director of Early Clinical Development at Denali Therapeutics, a South San Francisco biotech company focused on developing new treatments for neurodegenerative diseases. After completing medical school and a residency program in neurology in Madrid, Andrés moved to the US to pursue a postdoc at the University of California San Francisco, where his research focused on in vivo retinal imaging in preclinical models of neuroinflammation to develop translational biomarkers for disease progression and therapeutic response in demyelinating diseases such as Multiple Sclerosis. Andrés then did a Clinical Research Fellowship at Genentech-Roche, where he was involved in Phase 3 & 4 global clinical trials in multiple sclerosis and Alzheimer´s Disease, and joined Denali in 2019. In his free time, Andrés loves to go out on hikes and beach excursions with his wife, his 3 y.o. son, and his 10 month-old daughter.

RSVP: https://lnkd.in/gDifYAJT

Zoom: https://lnkd.in/gynKrJ8A